Advertisement

Impact of Beta Blockade Therapy on Long-Term Mortality After ST-Segment Elevation Acute Myocardial Infarction in the Percutaneous Coronary Intervention Era

Published:December 10, 2012DOI:https://doi.org/10.1016/j.amjcard.2012.10.026
      Although clinical guidelines recommend long-term β-blocker (BB) therapy to decrease mortality after acute myocardial infarction, these recommendations are based predominantly on evidence from before the reperfusion and thrombolytic eras. To investigate the effects of BB therapy for patients with acute myocardial infarctions on mortality in the percutaneous coronary intervention era, a total of 5,628 consecutive patients who were admitted <24 hours after the onset of ST-segment elevation myocardial infarction, treated with emergent percutaneous coronary intervention, and discharged alive were studied. During a median follow-up period of 1,430 days, mortality rates did not differ between patients with and without BB therapy (5.2% vs 6.2%, p = 0.786). Multivariate analysis revealed that BB treatment was not associated with a reduced risk for mortality (hazard ratio 0.935, 95% confidence interval 0.711 to 1.230, p = 0.534). The results of propensity score matching also indicated that the mortality rates did not differ between the 2 groups. However, subgroup analyses among matched populations revealed that BB treatment was associated with a significantly lower mortality risk for high-risk patients, who were defined as those with Global Registry of Acute Coronary Events (GRACE) risk scores ≥121 (hazard ratio 0.596, 95% confidence interval 0.416 to 0.854, p = 0.005) or those administered diuretics (hazard ratio 0.602, 95% confidence interval 0.398 to 0.910, p = 0.016), but not for lower risk patients. In conclusion, BB treatment was associated with reduced long-term mortality in patients after ST-segment elevation myocardial infarction at higher risk, but not in those at lower risk. Although randomized controlled studies are warranted to confirm these results, the implementation of BB therapy for discharged patients with ST-segment elevation myocardial infarction may need to be assessed on the basis of individual mortality risk in the percutaneous coronary intervention era.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Antman E.M.
        • Anbe D.T.
        • Armstrong P.W.
        • Bates E.R.
        • Green L.A.
        • Hand M.
        • Hochman J.S.
        • Krumholz H.M.
        • Kushner F.G.
        • Lamas G.A.
        • Mullany C.J.
        • Ornato J.P.
        • Pearle D.L.
        • Sloan M.A.
        • Smith Jr., S.C.
        • Alpert J.S.
        • Anderson J.L.
        • Faxon D.P.
        • Fuster V.
        • Gibbons R.J.
        • Gregoratos G.
        • Halperin J.L.
        • Hiratzka L.F.
        • Hunt S.A.
        • Jacobs A.K.
        • Ornato J.P.
        ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction).
        J Am Coll Cardiol. 2004; 44: E1-E211
        • Kushner F.G.
        • Hand M.
        • Smith Jr., S.C.
        • King III, S.B.
        • Anderson J.L.
        • Antman E.M.
        • Bailey S.R.
        • Bates E.R.
        • Blankenship J.C.
        • Casey Jr., D.E.
        • Green L.A.
        • Hochman J.S.
        • Jacobs A.K.
        • Krumholz H.M.
        • Morrison D.A.
        • Ornato J.P.
        • Pearle D.L.
        • Peterson E.D.
        • Sloan M.A.
        • Whitlow P.L.
        • Williams D.O.
        2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        Circulation. 2009; 120: 2271-2306
        • Van de Werf F.
        • Bax J.
        • Betriu A.
        • Blomstrom-Lundqvist C.
        • Crea F.
        • Falk V.
        • Filippatos G.
        • Fox K.
        • Huber K.
        • Kastrati A.
        • Rosengren A.
        • Steg P.G.
        • Tubaro M.
        • Verheugt F.
        • Weidinger F.
        • Weis M.
        • Vahanian A.
        • Camm J.
        • De Caterina R.
        • Dean V.
        • Dickstein K.
        • Filippatos G.
        • Funck-Brentano C.
        • Hellemans I.
        • Kristensen S.D.
        • McGregor K.
        • Sechtem U.
        • Silber S.
        • Tendera M.
        • Widimsky P.
        • Zamorano J.L.
        • Silber S.
        • Aguirre F.V.
        • Al-Attar N.
        • Alegria E.
        • Andreotti F.
        • Benzer W.
        • Breithardt O.
        • Danchin N.
        • Di Mario C.
        • Dudek D.
        • Gulba D.
        • Halvorsen S.
        • Kaufmann P.
        • Kornowski R.
        • Lip G.Y.
        • Rutten F.
        Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology.
        Eur Heart J. 2008; 29: 2909-2945
        • Lopez-Sendon J.
        • Swedberg K.
        • McMurray J.
        • Tamargo J.
        • Maggioni A.P.
        • Dargie H.
        • Tendera M.
        • Waagstein F.
        • Kjekshus J.
        • Lechat P.
        • Torp-Pedersen C.
        Expert consensus document on beta-adrenergic receptor blockers.
        Eur Heart J. 2004; 25: 1341-1362
      1. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results.
        JAMA. 1983; 250: 2814-2819
      2. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results.
        JAMA. 1982; 247: 1707-1714
      3. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction.
        N Engl J Med. 1981; 304: 801-807
        • Yusuf S.
        • Peto R.
        • Lewis J.
        • Collins R.
        • Sleight P.
        Beta blockade during and after myocardial infarction: an overview of the randomized trials.
        Prog Cardiovasc Dis. 1985; 27: 335-371
        • Freemantle N.
        • Cleland J.
        • Young P.
        • Mason J.
        • Harrison J.
        Beta blockade after myocardial infarction: systematic review and meta regression analysis.
        BMJ. 1999; 318: 1730-1737
        • Fox K.A.
        • Steg P.G.
        • Eagle K.A.
        • Goodman S.G.
        • Anderson Jr., F.A.
        • Granger C.B.
        • Flather M.D.
        • Budaj A.
        • Quill A.
        • Gore J.M.
        Decline in rates of death and heart failure in acute coronary syndromes 1999–2006.
        JAMA. 2007; 297: 1892-1900
        • Ford E.S.
        • Ajani U.A.
        • Croft J.B.
        • Critchley J.A.
        • Labarthe D.R.
        • Kottke T.E.
        • Giles W.H.
        • Capewell S.
        Explaining the decrease in U.S. deaths from coronary disease 1980–2000.
        N Engl J Med. 2007; 356: 2388-2398
        • Nakatani D.
        • Sakata Y.
        • Mizuno H.
        • Shimizu M.
        • Suna S.
        • Usami M.
        • Ito H.
        • Yasumura Y.
        • Hirayama A.
        • Takeda H.
        • Hori M.
        • Sato H.
        Impact of diabetes mellitus on rehospitalization for heart failure among survivors of acute myocardial infarction in the percutaneous coronary intervention era.
        Circ J. 2009; 73: 662-666
        • Eagle K.A.
        • Lim M.J.
        • Dabbous O.H.
        • Pieper K.S.
        • Goldberg R.J.
        • Van de Werf F.
        • Goodman S.G.
        • Granger C.B.
        • Steg P.G.
        • Gore J.M.
        • Budaj A.
        • Avezum A.
        • Flather M.D.
        • Fox K.A.
        A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry.
        JAMA. 2004; 291: 2727-2733
        • Rubin D.
        Inference and missing data.
        Biometrika. 1976; 63: 581-592
        • Rubin D.
        Multiple Imputation for Nonresponse in Surveys.
        John Wiley & Sons, New York, New York1987
        • D'Agostino Jr., R.B.
        Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.
        Stat Med. 1998; 17: 2265-2281
        • Wang A.
        • Pappas P.
        • Anstrom K.J.
        • Abrutyn E.
        • Fowler Jr, V.G.
        • Hoen B.
        • Miro J.M.
        • Corey G.R.
        • Olaison L.
        • Stafford J.A.
        • Mestres C.A.
        • Cabell C.H.
        The use and effect of surgical therapy for prosthetic valve infective endocarditis: a propensity analysis of a multicenter, international cohort.
        Am Heart J. 2005; 150: 1086-1091
        • Tarakji K.G.
        • Brunken R.
        • McCarthy P.M.
        • Al-Chekakie M.O.
        • Abdel-Latif A.
        • Pothier C.E.
        • Blackstone E.H.
        • Lauer M.S.
        Myocardial viability testing and the effect of early intervention in patients with advanced left ventricular systolic dysfunction.
        Circulation. 2006; 113: 230-237
        • Montalescot G.
        • Philippe F.
        • Ankri A.
        • Vicaut E.
        • Bearez E.
        • Poulard J.E.
        • Carrie D.
        • Flammang D.
        • Dutoit A.
        • Carayon A.
        • Jardel C.
        • Chevrot M.
        • Bastard J.P.
        • Bigonzi F.
        • Thomas D.
        French Investigators of the ESSENCE Trial. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin.
        Circulation. 1998; 98: 294-299
        • Segal M.R.
        Regression trees for censored data.
        Biometrics. 1988; 44: 35-48
        • Antman E.M.
        • Hand M.
        • Armstrong P.W.
        • Bates E.R.
        • Green L.A.
        • Halasyamani L.K.
        • Hochman J.S.
        • Krumholz H.M.
        • Lamas G.A.
        • Mullany C.J.
        • Pearle D.L.
        • Sloan M.A.
        • Smith Jr., S.C.
        • Anbe D.T.
        • Kushner F.G.
        • Ornato J.P.
        • Pearle D.L.
        • Sloan M.A.
        • Jacobs A.K.
        • Adams C.D.
        • Anderson J.L.
        • Buller C.E.
        • Creager M.A.
        • Ettinger S.M.
        • Halperin J.L.
        • Hunt S.A.
        • Lytle B.W.
        • Nishimura R.
        • Page R.L.
        • Riegel B.
        • Tarkington L.G.
        • Yancy C.W.
        2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2008; 51: 210-247
        • McMurray J.
        • Kober L.
        • Robertson M.
        • Dargie H.
        • Colucci W.
        • Lopez-Sendon J.
        • Remme W.
        • Sharpe D.N.
        • Ford I.
        Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial.
        J Am Coll Cardiol. 2005; 45: 525-530
        • Doughty R.N.
        • Whalley G.A.
        • Walsh H.A.
        • Gamble G.D.
        • Lopez-Sendon J.
        • Sharpe N.
        Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy.
        Circulation. 2004; 109: 201-206
        • Chadda K.
        • Goldstein S.
        • Byington R.
        • Curb J.D.
        Effect of propranolol after acute myocardial infarction in patients with congestive heart failure.
        Circulation. 1986; 73: 503-510
        • Gottlieb S.S.
        • McCarter R.J.
        • Vogel R.A.
        Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction.
        N Engl J Med. 1998; 339: 489-497
        • Gordon L.
        • Olshen R.A.
        Tree-structured survival analysis.
        Cancer Treat Rep. 1985; 69: 1065-1069
        • Segal M.R.
        Features of tree-structured survival analysis.
        Epidemiology. 1997; 8: 344-346
        • Tuppin P.
        • Neumann A.
        • Danchin N.
        • de Peretti C.
        • Weill A.
        • Ricordeau P.
        • Allemand H.
        Evidence-based pharmacotherapy after myocardial infarction in France: adherence-associated factors and relationship with 30-month mortality and rehospitalization.
        Arch Cardiovasc Dis. 2010; 103: 363-375
        • Bellenger N.G.
        • Burgess M.I.
        • Ray S.G.
        • Lahiri A.
        • Coats A.J.
        • Cleland J.G.
        • Pennell D.J.
        Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable?.
        Eur Heart J. 2000; 21: 1387-1396